A Boston-based asset management firm specializing in health care investing said today it has closed a biotechnology fund to new investors.

MPM Capital’s BioEquities Fund has garnered more than $400 million since it started in March of last year, the company said. The assets now total more than $450 million. The fund shut down to new investors Jan. 2.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.